- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03796533
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity (Posa-Pk)
Among its authorized indications, posaconazole (PCZ) is prescribed for prophylaxis in onco-hematology patients at high risk of invasive fungal infections. This azole antifungal has a low bioavailability. The enteric-coated tablets form available since mid-2015 has significantly improved its pharmacokinetic profile compared to the oral suspension form initially used. According to the recommendations of The European Conference on Infections in Leukemia (ECIL-6), the minimum serum concentration desirable for prophylaxis is 0.7 mg/L. This concentration threshold was difficult to achieve in onco-hematology patients treated with oral suspension.
The investigators retrospectively collected and analyzed 201 results of residual PCZ serum concentrations from 91 onco-hematology patients on Noxafil® tablets prophylaxis. The median concentration of PCZ was 1.08 mg/L. In this study, the pharmacokinetics of tablet-PCZ showed significant inter-individual variability. Thus, while 25% of the concentrations remained below the recommended threshold of 0.7 mg/L (25% percentile = 0.69 mg/L), exposure to PCZ was greater than 2.63 mg/L in 10% of cases. This level of exposure, however, did not have obvious hepatic repercussions. Nevertheless, further studies involving larger cohorts are needed to clarify a hypothetical relationship between serum PCZ concentration and the occurrence of hepatic toxicity.
In addition, the investigators found significant intra-individual variability in PCZ exposure (CV = 48.8%), especially in leukemic patients. This variability is probably related to a modification during the treatment of the physio-pathological conditions of the patient likely to impact the pharmacokinetics of PCZ (absorption, distribution, metabolism, etc.) as well as the effect of possible pharmacokinetic drug interactions.
The metabolism of PCZ is mediated primarily by the uridine diphosphate (UDP)-glucuronosyltransferase 1A4 (UGT1A4) pathway. Although hepatic metabolism of PCZ is low compared with other azoles (such as itraconazole or voriconazole), differences in the metabolic capacity of UGT1A4 may alter PCZ exposure. A previous study of the oral suspension form had shown that low concentrations of PCZ were associated with a high ratio of PCZ-glucuronide / PCZ concentrations. Two genetic variants of the gene encoding UGT1A4 are associated with a decrease in the metabolic clearance of glucuronide drugs via UGT1A4. A recent study suggests less exposure to PCZ in the presence of UGT1A4 polymorphism.
The main objective of the investigator's project is to study prospectively in a homogeneous population of patients treated by intensive chemotherapy for acute myeloid leukemia (induction and consolidation) the pharmacokinetics of PCZ administered in its tablet formulation, and in particular:
- Clinical and biological tolerance of high concentrations of PCZ
- The influence of clinical and demographic covariates on PCZ and PCZ-glucuronide ratio
- The influence of genetic variants of UGT1A4 on PCZ metabolism (PCZ-glucuronide / PCZ ratio).
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sophie Ducastelle-lepretre
- Phone Number: +33 04 78 86 22 36
- Email: Sophie.ducastelle-lepretre@chu-lyon.fr
Study Contact Backup
- Name: Mohamed EL HAMRI
- Phone Number: +33 04 78 86 22 20
- Email: mohamed.el-hamri@chu-lyon.fr
Study Locations
-
-
-
Pierre-Bénite, France
- Recruiting
- Centre Hospitalier Lyon Sud, Hematology department
-
Sub-Investigator:
- Marie Balsat, MD
-
Sub-Investigator:
- Fiorenza Barraco, MD
-
Sub-Investigator:
- Gaëlle Fossard, MD
-
Contact:
- Sophie DUCASTELLE-LEPRETRE, MD
- Phone Number: +33 04 78 86 22 36
- Email: Sophie.ducastelle-lepretre@chu-lyon.fr
-
Contact:
- Mohamed EL HAMRI, MD
- Phone Number: +33 04 78 86 22 20
- Email: mohamed.el-hamri@chu-lyon.fr
-
Principal Investigator:
- Sophie Ducastelle-Lepretre, MD
-
Sub-Investigator:
- Xavier THOMAS, MD
-
Sub-Investigator:
- Etienne PAUBELLE, MD
-
Sub-Investigator:
- Hélène Labussiere-Wallet, MD
-
Sub-Investigator:
- Eric Wattel
-
Sub-Investigator:
- Marie Virginie Larcher, MD
-
Sub-Investigator:
- Clement Rocher, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient aged 18 or over
- Patients with AML de novo or secondary to myelodysplastic syndrome or therapy-related AML except acute myeloid leukemia (AML3)
- Patient hospitalized for the treatment of leukemia (induction chemotherapy or consolidation)
- General state retained (ECOG performance scale ≤ 3)
- alanine aminotransferase aspartate transaminase (ASAT) and alanine aminotransferase (ALAT) ≤ 2.5 times the upper limit of normal (ULN), total bilirubin ≤ 2 times the ULN, creatinine <150 μmol / L unless these biological abnormalities are related to leukemia
- Patients affiliated or beneficiaries of a social security scheme (Social Security or Universal Medical Coverage)
- Having read and understood the information sheet and signed the informed consent
Exclusion Criteria:
- Patients with acute promyelocytic leukemia (AML3)
- History of uncontrolled cancer for at least two years
- Patient included in another clinical study that may interfere with the objectives of this study
- Treatment with antifungal other than posaconazole
- Severe uncontrolled infection at the time of inclusion
- Positive serology for HIV 1 or 2 or human T-cell lymphoma virus (HTLV 1) or 2, or active viral infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Pregnant woman (beta positive HCG) or breastfeeding
- A woman of childbearing potential who can not justify the use of effective contraception during treatment with Noxafil®
- Patient incapacitated, under guardianship, curators or safeguard of justice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Posaconazole pharmacokinetics
Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of the blood concentration of posaconazole and its metabolite from the beginning of treatment to the end of the induction phase (pharmacokinetic).
Time Frame: Day 21
|
Posaconazole (PCZ) treatment will start at Day 1 at the beginning of induction/ consolidation therapy.
|
Day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Search and identification by sequencing gene variants of UGT1A4
Time Frame: At diagnosis
|
The blood sample (5 mL) for the study of polymorphisms of the UGT1A4 gene will be performed before the initiation of induction.
|
At diagnosis
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- 14-alpha Demethylase Inhibitors
- Trypanocidal Agents
- Posaconazole
Other Study ID Numbers
- 69HCL18_0429
- 2018-003488-67 (Other Identifier: ID-RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid, Acute
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on Posaconazole
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCCompletedInvasive AspergillosisBelgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
-
Bayside HealthMerck Sharp & Dohme LLCUnknownFungal InfectionAustralia
-
Merck Sharp & Dohme LLCCompleted
-
Radboud University Medical CenterMerck Sharp & Dohme LLC; St. Antonius HospitalCompleted
-
Merck Sharp & Dohme LLCRecruitingInvasive Fungal InfectionIsrael, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
-
Merck Sharp & Dohme LLCCompleted
-
National Cancer Centre, SingaporeNational Medical Research Council (NMRC), SingaporeRecruitingMetastatic Triple-Negative Breast CarcinomaSingapore
-
Nissan Chemical IndustriesCompletedIntermittent Claudication | Peripheral Vascular DiseaseUnited States
-
Bambino Gesù Hospital and Research InstituteRadboud University Medical Center; University of Exeter; Consorzio per Valutazioni...RecruitingCystic Fibrosis | AspergillosisIreland, Spain, Netherlands, France, United Kingdom, Czechia, Germany, Greece, Italy, Portugal, Switzerland